Technical Data
N2050-10K
Nerve Growth Factor, beta, Recombinant, Human (Beta-nerve Growth Factor, Beta-NGF, NGFb, NGF, HSAN5, MGC161426, MGC161428)
1 Vial
Molecular Biology Storage: -20CShipping: Blue Ice
Source:
Recombinant corresponding to 119aa of human beta-Nerve Growth Factor expressed in E.coli is a homodimer, glycosylated, polypeptide chain.

Molecular Weight:
~17kD

Biological Activity:
The ED50,calculated by its ability to stimulate chick E9 DRG neurite outgrowth was found to be 1x106 units/mg.

Dimers and Aggregates:
1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods:1.UV spectroscopy at 280nm using the absorbency value of 1.1945 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of Recombinant corresponding to beta-Nerve Growth Factor as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~17kD
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: Not determined
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. The statistical mechanics of complex signaling networks: nerve growth factor signaling.Phys Biol 2004 Dec;1(3-4):184-95. 2. Intraventricular nerve growth factor infusion: a possible treatment for neurological deficits following hypoxic-ischemic brain injury in infants. Neurol Res 2005 Oct;27(7):741-6. 3. Nerve growth factor-induced expression of the GTP cyclohydrolase I gene via Ras/MEK pathway in PC12D cells. J Neurochem 2005 Oct;95(2):563-9. 4. Spatio-temporal activation of cyclic AMP response element-binding protein, activity-regulated cytoskeletal-associated protein and brain-derived nerve growth factor: a mechanism for pontine-wave generator activation-dependent two-way active-avoidance memory processing in the rat. J Neurochem 2005 Oct;95(2):418-28. 5. Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats. Invest Ophthalmol Vis Sci 2005 Oct;46(10):3800-6. 6. Nerve growth factor mediates its pro-invasive effect in parallel with the release of a soluble E-cadherin fragment from breast cancer MCF-7/AZ cells. J Dairy Res 2005;72 Spec No:20-6.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.